![Adolf Hoess](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Adolf Hoess
Algemeen Directeur bij Affimed NV Niederlassung Deutschland
Vermogen: 1 M $ op 31-05-2024
Actieve functies van Adolf Hoess
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Algemeen Directeur | - | - |
Affimed GmbH
![]() Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Algemeen Directeur | 01-09-2011 | - |
Loopbaan van Adolf Hoess
Eerdere bekende functies van Adolf Hoess
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AFFIMED N.V. | Directeur/Bestuurslid | 01-10-2010 | 15-01-2024 |
Algemeen Directeur | 01-09-2011 | 15-01-2024 | |
Corporate Officer/Principal | 01-10-2010 | 01-09-2011 | |
Carl Zeiss Jena GmbH
![]() Carl Zeiss Jena GmbH Medical SpecialtiesHealth Technology Carl Zeiss Jena GmbH engages in the design, prototyping, batch production, and testing of optical systems, single components, and auxiliary materials. It also provides services such as calibration, sampling of injection-molded and machined parts, hardness testing, heat treatment of materials, electromagnetic compatibility testing, and environmental simulation. The company is headquartered in Jena, Germany. | Corporate Officer/Principal | 01-01-2002 | 01-01-2002 |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-01-1993 | 01-01-1993 |
Jenowis AG | Algemeen Directeur | - | - |
Amphivena Therapeutics, Inc.
![]() Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Directeur/Bestuurslid | - | - |
MORPHOSYS AG | Corporate Officer/Principal | 01-01-1993 | - |
Shire Orphan Therapies GmbH
![]() Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | - | - |
Opleiding van Adolf Hoess
Technische Universität München | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Statistieken
Internationaal
Duitsland | 10 |
Verenigde Staten | 3 |
Operationeel
Corporate Officer/Principal | 5 |
Chief Executive Officer | 4 |
Doctorate Degree | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 4 |
Retail Trade | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AFFIMED N.V. | Health Technology |
MORPHOSYS AG | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Carl Zeiss Jena GmbH
![]() Carl Zeiss Jena GmbH Medical SpecialtiesHealth Technology Carl Zeiss Jena GmbH engages in the design, prototyping, batch production, and testing of optical systems, single components, and auxiliary materials. It also provides services such as calibration, sampling of injection-molded and machined parts, hardness testing, heat treatment of materials, electromagnetic compatibility testing, and environmental simulation. The company is headquartered in Jena, Germany. | Health Technology |
Shire Orphan Therapies GmbH
![]() Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
Amphivena Therapeutics, Inc.
![]() Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Jenowis AG | |
Affimed GmbH
![]() Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
- Beurs
- Insiders
- Adolf Hoess
- Ervaring